Literatur
-
1
Barie P S.
Drotrecogin alfa (activated) has a favorable benefit/risk profile in surgical patients with severe sepsis.
Crit Care Med.
2002;
30
A 102
-
2 Bernard G R. Early administration of Drotrecogin alfa (activated) improves survival, reduces costs of treating patients with severe sepsis. http://www.peerviewpress.com/search.do?month=11&year=2003&keyword=Bernard
-
3
Boldt J.
Können wir uns die Fortschritte in der Intensivmedizin noch leisten?.
Dtsch Med Wochenschr.
2004;
129
36-40
-
4
Laffan M OC, Niamh M, Perry D J, Hodgson A J, O’Shaughnessy D, Smith O P.
Analysis and results of the recombinant factor VIIa extended-use registry.
Blood Coagul and Fibrinolysis.
2003;
14
S35-S38
-
5
Reinhardt K, Brunkhorst F M, Bloos F.
Fortschritte in der Therapie der Sepsis.
Dtsch Arzteblatt.
2003;
100
A 2080-2086
-
6
Rivers E, Nguyen B, Havstad S. et al .
Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock.
N Engl J Med.
2001;
345
1368-1377
-
7
Sanmuganathan P S, Ghahramani P, Jackson P R, Wallis E J, Ramsay L E.
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Heart.
2001;
85
265-271
Dr. Armin Kalenka
Institut für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Mannheim
Theodor Kutzer Ufer 1-3
68167 Mannheim
Phone: 0621/3833233
Fax: 0621/3832021
Email: armin.kalenka@anaes.ma.uni-heidelberg.de
